Lantus

Insulin glargine, the active ingredient in Lantus, is a long‑acting insulin analog presented as an injection solution for subcutaneous use. It provides basal insulin coverage to control chronic hyperglycemia in adults and children with type 1 or type 2 diabetes mellitus, helping maintain stable fasting glucose levels. The molecule binds to insulin receptors with a prolonged duration, delivering a steady release over 24 hours.

GNH USA supplies Lantus as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product complies with EU regulatory standards and is distributed under controlled temperature conditions.

Lantus (insulin glargine) is a basal insulin used to manage chronic hyperglycemia in diabetes. - Type 1 diabetes mellitus: provides steady basal insulin to reduce fasting glucose and lower risk of ketoacidosis. - Type 2 diabetes mellitus: complements oral agents or rapid‑acting insulin to maintain basal insulin levels and improve overall glycemic control. - Pediatric type 1 diabetes mellitus (≥2 years): delivers consistent basal insulin, supporting growth and development while simplifying dosing schedules.

Lantus may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Hypoglycemia: low blood glucose episodes, especially if meals are missed or dosing is excessive. - Injection site reactions: redness, swelling, or itching at the injection site. - Weight gain: gradual increase in body weight associated with improved glycemic control. - Lipodystrophy: localized thickening or lipoatrophy of subcutaneous tissue. - Edema: mild peripheral swelling, often in the lower extremities. - Headache: transient mild to moderate head pain.

Serious or Rare Side Effects: - Severe hypoglycemia: profound low glucose requiring assistance. - Anaphylactic reaction: sudden onset of rash, swelling, airway compromise. - Insulin allergy: systemic urticaria or angioedema. - Insulin antibodies: may alter insulin action and cause unpredictable glucose levels. - Diabetic ketoacidosis (rare): despite basal insulin, may occur if insulin absorption is impaired. - Necrotizing fasciitis at injection site (extremely rare).

When using Lantus, several precautions should be observed to ensure safe and effective therapy. - Dose titration: adjust dose gradually based on self‑monitored blood glucose and clinical response. - Hypoglycemia risk: educate patients to recognize symptoms and have fast‑acting carbohydrate available. - Illness management: monitor glucose more frequently and consider temporary dose adjustments during infection or stress. - Renal/hepatic impairment: use lower initial doses and monitor closely for accumulation. - Pregnancy and lactation: safety data are limited; prescribe only if benefits outweigh potential risks. - Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake the vial.

Lantus can interact with other medicines, influencing glucose levels or insulin action.

Major Interactions (Avoid): - Sulfonylureas or meglitinides: combined use markedly increases risk of severe hypoglycemia. - Pramlintide: concurrent administration may cause additive hypoglycemic effect. - Systemic corticosteroids: can antagonize insulin action, leading to uncontrolled hyperglycemia.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask hypoglycemia symptoms, requiring closer glucose monitoring. - ACE inhibitors or ARBs: may enhance insulin sensitivity, potentially necessitating dose reduction. - Thiazide diuretics: can raise blood glucose, warranting periodic assessment. - Oral contraceptives: may alter insulin requirements during hormonal changes.